The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|April 28, 2020
The Typical Rules for a Rheumatology Visit Have Changed
In this interview with Rheumatology Network, Dr. Andrew Concoff, Executive Vice President and Chief Value Officer of United Rheumatology, discusses how the typical rheumatology patient visit has changed during the coronavirus pandemic.
Advertisement
In this interview with Rheumatology Network, Dr. Andrew Concoff, Executive Vice President and Chief Value Officer of United Rheumatology, discusses how the typical rheumatology patient visit has changed during the coronavirus pandemic.
Advertisement
Related to this article
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
The designation follows phase 2 IMPACT trial data showing reduced adverse pregnancy outcomes in high-risk antiphospholipid syndrome.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
Advertisement
Advertisement